secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2022-04-29T23:59:59+00:00
Accession:  0000014272-22-000112
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bristol-Myers Q1 revenue $11.6B (+5%); Non-GAAP EPS $1.96 (+13%)
----------------------------------------------------------------

- Revenue $11.648B, +5% YoY (7% ex FX); U.S. revenue $7.7B (+10%).
- GAAP EPS $0.59 (down 34%); Non-GAAP EPS $1.96 (up 13%); net $(0.10) Acquired IPRD impact.
- In-line products +8% (Eliquis $3.2B +11%, Opdivo $1.9B +12%).
- Revlimid $2.8B (-5%) and Abraxane $214M (-32%) as LOE pressures continue.
- FDA approved Opdualag (melanoma) and Camzyos (cardiomyopathy) in Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000001427222000112/0000014272-22-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000001427222000112/bmy-20220429.htm
  HTML page:      https://secwatch.observer/filing/0000014272-22-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer